---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001388"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-25T00:31:01.360394+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Anika completes sale of Parcus Medical for $4.5M cash, sharpens focus on OA pain management

## Summary
- Sale closed March 7, 2025 to Medacta Group SA (Medacta Americas Manufacturing).
- Cash consideration of $4.5M at closing, subject to customary post-closing adjustments.
- Divestiture part of previously announced strategic review; company to focus on hyaluronic acid and regenerative solutions.
- Parcus Medical was a wholly owned subsidiary; Anika received total cash consideration at closing.
- Goodwin Procter served as legal counsel; Piper Sandler as exclusive financial advisor to Anika.

## SEC filing metadata
- accession: 0001171843-25-001388
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184325001388/0001171843-25-001388-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184325001388/f8k_031025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001388
- JSON: https://secwatch.observer/filing/0001171843-25-001388.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001388.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.